HomeCompareIPSEY vs QYLD

IPSEY vs QYLD: Dividend Comparison 2026

IPSEY yields 0.86% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPSEY wins by $2.6K in total portfolio value
10 years
IPSEY
IPSEY
● Live price
0.86%
Share price
$46.30
Annual div
$0.40
5Y div CAGR
33.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$2,101.14
Full IPSEY calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — IPSEY vs QYLD

📍 IPSEY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEYQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEY + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEY pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEY
Annual income on $10K today (after 15% tax)
$73.26/yr
After 10yr DRIP, annual income (after tax)
$1,785.97/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $3,024.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEY + QYLD for your $10,000?

IPSEY: 50%QYLD: 50%
100% QYLD50/50100% IPSEY
Portfolio after 10yr
$26.7K
Annual income
$3,880.23/yr
Blended yield
14.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IPSEY right now

IPSEY
Analyst Ratings
2
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
14.0
Piotroski
7/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEY buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEYQYLD
Forward yield0.86%11.92%
Annual dividend / share$0.40$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.9%0%
Portfolio after 10y$28.0K$25.4K
Annual income after 10y$2,101.14$5,659.31
Total dividends collected$7.1K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: IPSEY vs QYLD ($10,000, DRIP)

YearIPSEY PortfolioIPSEY Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$10,815$115.41$10,352$1,192.36+$463.00IPSEY
2$11,729$156.20$10,830$1,347.57+$899.00IPSEY
3$12,762$211.97$11,460$1,539.07+$1.3KIPSEY
4$13,944$288.63$12,275$1,777.84+$1.7KIPSEY
5$15,314$394.64$13,323$2,078.95+$2.0KIPSEY
6$16,929$542.40$14,667$2,463.34+$2.3KIPSEY
7$18,864$750.31$16,396$2,960.57+$2.5KIPSEY
8$21,231$1,046.28$18,631$3,612.97+$2.6KIPSEY
9$24,191$1,473.60$21,548$4,482.15+$2.6KIPSEY
10$27,985$2,101.14$25,398$5,659.31+$2.6KIPSEY

IPSEY vs QYLD: Complete Analysis 2026

IPSEYStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEY Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this IPSEY vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEY vs SCHDIPSEY vs JEPIIPSEY vs OIPSEY vs KOIPSEY vs MAINIPSEY vs XYLDIPSEY vs JEPQIPSEY vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.